Matching articles for "amiodarone"
Issue 1728 · May 12, 2025
Landiolol (Rapiblyk) for Short-Term Rate Control in Supraventricular Tachycardia

The FDA has approved the intravenously administered beta 1 -adrenergic blocker landiolol ( Rapiblyk – AOP) for short-term reduction of ventricular rate in adults with supraventricular tachycardia including…

Med Lett Drugs Ther. 2025 May 12; 67(1728):75-6 doi:10.58347/tml.2025.1728b
The FDA has approved the intravenously administered beta 1 -adrenergic blocker landiolol ( Rapiblyk – AOP) for short-term reduction of ventricular rate in adults with supraventricular tachycardia including atrial fibrillation and atrial flutter. Esmolol ( Brevibloc , and generics), another IV beta blocker, was approved earlier for the same indication.
Issue 1693 · January 8, 2024
Treatment of Atrial Fibrillation

Atrial fibrillation (AF) is the most common arrhythmia in the world. Risk factor modification, anticoagulation, rhythm control, and rate control are the four pillars of its management. American College of…

Med Lett Drugs Ther. 2024 Jan 8; 66(1693):1-8 doi:10.58347/tml.2024.1693a
Atrial fibrillation (AF) is the most common arrhythmia in the world. Risk factor modification, anticoagulation, rhythm control, and rate control are the four pillars of its management. American College of Cardiology/American Heart Association (ACC/AHA) guidelines on management of AF were updated recently.
Issue 1580 · September 9, 2019
Drugs for Atrial Fibrillation

Treatment of atrial fibrillation includes anticoagulation, rate control, and rhythm control. US guidelines were recently updated.

Med Lett Drugs Ther. 2019 Sep 9; 61(1580):137-44
Treatment of atrial fibrillation includes anticoagulation, rate control, and rhythm control. US guidelines were recently updated.
Issue 1480 · October 26, 2015
Drugs for Hypothyroidism

Primary hypothyroidism is usually the result of Hashimoto's thyroiditis, thyroidectomy, or radioactive iodine therapy. Treatment of hypothyroidism with replacement doses of thyroid hormone is usually lifelong.…

Med Lett Drugs Ther. 2015 Oct 26; 57(1480):147-50
Primary hypothyroidism is usually the result of Hashimoto's thyroiditis, thyroidectomy, or radioactive iodine therapy. Treatment of hypothyroidism with replacement doses of thyroid hormone is usually lifelong. Levothyroxine is the drug of choice.
Issue 1479 · October 12, 2015
Daclatasvir (Daklinza) for HCV Genotype 3 Infection

The FDA has approved daclatasvir ( Daklinza – BMS), an oral direct-acting antiviral drug, for use with sofosbuvir (Sovaldi) for treatment of chronic hepatitis C virus (HCV) genotype 3 infection. Daclatasvir…

Med Lett Drugs Ther. 2015 Oct 12; 57(1479):142-3
The FDA has approved daclatasvir ( Daklinza – BMS), an oral direct-acting antiviral drug, for use with sofosbuvir (Sovaldi) for treatment of chronic hepatitis C virus (HCV) genotype 3 infection. Daclatasvir is the first drug approved for this indication that does not require the addition of interferon or ribavirin. It is approved in Japan and Europe in combination with other drugs for treatment of HCV genotypes 1-4.
Issue 1466 · April 13, 2015 Free
In Brief: Severe Bradycardia with Sofosbuvir and Amiodarone

The FDA recently announced changes in the labeling of the hepatitis C drugs Sovaldi (sofosbuvir) and Harvoni (sofosbuvir/ledipasvir) to warn about a risk of serious and potentially fatal bradycardia when…

Med Lett Drugs Ther. 2015 Apr 13; 57(1466):58
The FDA recently announced changes in the labeling of the hepatitis C drugs Sovaldi (sofosbuvir) and Harvoni (sofosbuvir/ledipasvir) to warn about a risk of serious and potentially fatal bradycardia when either drug is taken with the antiarrhythmic drug amiodarone ( Cordarone , and others). 1 Symptomatic bradycardia was reported following initiation of treatment with Harvoni or with Sovaldi plus simeprevir (Olysio) or the investigational antiviral drug daclatasvir in 9 patients already taking amiodarone; it occurred within 24 hours of starting hepatitis C therapy in 6 patients and within 2-12 days in 3 others. One patient died of cardiac arrest and 3 required pacemaker implantation. In 3 patients who continued taking amiodarone, rechallenge with Harvoni or Sovaldi resulted in recurrence of symptomatic bradycardia. In another patient, rechallenge 8 weeks after stopping amiodarone did not result in bradycardia. The mechanism of this effect is unknown. Factors possibly contributing to the cardiac events include concomitant beta blocker therapy (in 7 patients) and preexisting cardiac and hepatic disease. Hepatic impairment increases the risk of cardiac conduction abnormalities and could increase adverse effects of amiodarone, which is metabolized by the liver. 2 Use of sofosbuvir without amiodarone has not been associated with significant bradycardia. The new labels warn that sofosbuvir and amiodarone should not be taken concurrently. If concomitant use is necessary, cardiac monitoring in an inpatient setting is recommended for the first 48 hours. Daily monitoring of heart rate, either at home or in an outpatient setting, should continue for at least the first 2 weeks of treatment. Amiodarone has a very long half-life, and its effects may persist for weeks to months after discontinuation. FDA. FDA Drug Safety Communication: FDA warns of serious slowing of the heart rate when antiarrhythmic drug amiodarone is used with hepatitis C treatments containing sofosbuvir Harvoni or Sovaldi in combination with another direct acting antiviral drug. Available at http://www.fda.gov. Accessed April 2, 2015. U Klotz. Antiarrhythmics: elimination and dosage considerations in hepatic impairment. Clin Pharmacokinet 2007; 46:985. Download complete U.S. English article
Issue 1461 · February 2, 2015
A 4-Drug Combination (Viekira Pak) for Hepatitis C

The FDA has approved Viekira Pak (Abbvie), a fixed-dose combination of two new direct-acting antiviral agents (ombitasvir, paritaprevir) with the pharmacologic enhancer ritonavir in one tablet, co-packaged…

Med Lett Drugs Ther. 2015 Feb 2; 57(1461):15-7
The FDA has approved Viekira Pak (Abbvie), a fixed-dose combination of two new direct-acting antiviral agents (ombitasvir, paritaprevir) with the pharmacologic enhancer ritonavir in one tablet, co-packaged with a third new direct-acting antiviral agent (dasabuvir) in a second tablet, for oral treatment of chronic hepatitis C virus (HCV) genotype 1 infection. Genotype 1 is responsible for 70-80% of HCV infections in the US.
Issue 1446 · July 7, 2014
Treatment of Atrial Fibrillation

The treatment of atrial fibrillation includes anticoagulation, rate control, and rhythm control. New US guidelines for the management of atrial fibrillation have recently been published.

Med Lett Drugs Ther. 2014 Jul 7; 56(1446):53-8
The treatment of atrial fibrillation includes anticoagulation, rate control, and rhythm control. New US guidelines for the management of atrial fibrillation have recently been published.
Issue 1379 · December 12, 2011
Safety of Dronedarone (Multaq)

Dronedarone ( Multaq – Sanofi), an analog of amiodarone, was approved by the FDA in 2009 for oral treatment of paroxysmal or persistent (non-permanent) atrial fibrillation or atrial flutter. Amiodarone (…

Med Lett Drugs Ther. 2011 Dec 12; 53(1379):103-4
Dronedarone ( Multaq – Sanofi), an analog of amiodarone, was approved by the FDA in 2009 for oral treatment of paroxysmal or persistent (non-permanent) atrial fibrillation or atrial flutter. Amiodarone ( Cordarone , and others) is more effective for this indication, but its use is often limited by its adverse effects, including thyroid and pulmonary toxicity.
Issue 1374 · October 3, 2011
Quetiapine (Seroquel) and QT-Interval Prolongation

The FDA has required the manufacturer of the secondgeneration antipsychotic quetiapine (Seroquel) to add a warning to the labeling saying that use of the drug should be avoided in combination with other drugs…

Med Lett Drugs Ther. 2011 Oct 3; 53(1374):79-80
The FDA has required the manufacturer of the secondgeneration antipsychotic quetiapine (Seroquel) to add a warning to the labeling saying that use of the drug should be avoided in combination with other drugs that prolong the electrocardiographic QTc interval (Table 1). The warning is based only on postmarketing reports of QT-interval prolongation in patients who overdosed on the drug, had concomitant illness, or were taking other drugs known to cause electrolyte imbalances or increase the QT interval. QT prolongation can lead to torsades de pointes, a potentially fatal cardiac arrhythmia.
Issue 1370 · August 8, 2011
New Simvastatin Dosing Recommendations

The FDA has announced changes in the labeling of simvastatin to reduce the risk of myopathy. These changes include limiting the use of the 80-mg maximum dose to patients who have been taking it for 12 months…

Med Lett Drugs Ther. 2011 Aug 8; 53(1370):61-2
The FDA has announced changes in the labeling of simvastatin to reduce the risk of myopathy. These changes include limiting the use of the 80-mg maximum dose to patients who have been taking it for 12 months or more without evidence of myopathy and new recommendations for use of simvastatin with other drugs. Simvastatin is available alone ( Zocor , and others) and in combination with ezetimibe (Vytorin) and with niacin (Simcor) .
Issue 1359 · March 7, 2011 Free
In Brief: FDA Warning on Dronedarone (Multaq)

The FDA and the manufacturer (Sanofi-Aventis) have warned healthcare professionals that use of dronedarone (Multaq) , an analog of amiodarone ( Cordarone , and others) approved in 2009 for treatment of atrial…

Med Lett Drugs Ther. 2011 Mar 7; 53(1359):17
The FDA and the manufacturer (Sanofi-Aventis) have warned healthcare professionals that use of dronedarone (Multaq) , an analog of amiodarone ( Cordarone , and others) approved in 2009 for treatment of atrial fibrillation, 1,2 has been associated with "several" cases of severe liver injury and hepatic failure, including two that required liver transplants. Both transplants were in women about 70 years old; one had taken the drug for 4.5 months and the other for 6 months. According to the FDA, 147,000 patients have taken dronedarone. 3 A new warning in the package insert recommends monitoring hepatic enzymes, especially during the first 6 months of treatment. 1. Dronedarone (Multaq) for atrial fibrillation. Med Lett Drugs Ther 2009; 51:78. 2. Treatment of atrial fibrillation. Treat Guidel Med Lett 2010; 8:65. 3. FDA drug safety podcast for healthcare professionals: severe liver injury associated with the use of dronedarone (marketed as Multaq). Available at www.fda.gov. Accessed February 24, 2011. Download U.S. English
Issue 97 · September 1, 2010
Treatment of Atrial Fibrillation

The treatment of atrial fibrillation includes ventricular rate control, anticoagulation, conversion to normal sinus rhythm and maintenance of sinus rhythm. The choice of therapies that can achieve these goals…

Treat Guidel Med Lett. 2010 Sep; 8(97):65-70
The treatment of atrial fibrillation includes ventricular rate control, anticoagulation, conversion to normal sinus rhythm and maintenance of sinus rhythm. The choice of therapies that can achieve these goals is discussed in the text that follows. Some drugs are recommended here for indications that have not been approved by the FDA.
Issue 1322 · October 5, 2009
Dronedarone (Multaq) for Atrial Fibrillation

Dronedarone ( Multaq - Sanofi-Aventis) has been approved by the FDA for oral treatment of atrial fibrillation and flutter. Amiodarone (Cordarone, and others) is the most effective drug for this indication, but…

Med Lett Drugs Ther. 2009 Oct 5; 51(1322):78-80
Dronedarone ( Multaq - Sanofi-Aventis) has been approved by the FDA for oral treatment of atrial fibrillation and flutter. Amiodarone (Cordarone, and others) is the most effective drug for this indication, but has considerable toxicity.
Issue 84 · August 1, 2009
Drugs for Thyroid Disorders

Primary hypothyroidism is usually the result of Hashimoto's thyroiditis, thyroidectomy for hyperthyroidism, goiter or cancer, or radioactive iodine therapy for hyperthyroidism.

Treat Guidel Med Lett. 2009 Aug; 7(84):57-64
Primary hypothyroidism is usually the result of Hashimoto's thyroiditis, thyroidectomy for hyperthyroidism, goiter or cancer, or radioactive iodine therapy for hyperthyroidism.
Issue 1297 · October 20, 2008
Drug Interactions with Simvastatin

A recent letter to the editor of the Annals of Internal Medicine documented a single case of myopathy apparently due to an interaction between simvastatin ( Zocor , and others) and green tea. Since it became…

Med Lett Drugs Ther. 2008 Oct 20; 50(1297):83-4
A recent letter to the editor of the Annals of Internal Medicine documented a single case of myopathy apparently due to an interaction between simvastatin ( Zocor , and others) and green tea. Since it became available generically, simvastatin has surpassed atorvastatin ( Lipitor ) as the best selling statin. As such, it is probably the most common cause of statin-induced myopathy, which is often a result of drug interactions.
Issue 1288 · June 16, 2008 Free
Addendum: Warfarin-Acetaminophen Interaction

A reader expressed disappointment that our recent listing of “Some Warfarin Drug Interactions” 1 did not include acetaminophen. Perhaps it should have. Acetaminophen can increase the anticoagulant effect…

Med Lett Drugs Ther. 2008 Jun 16; 50(1288):45
A reader expressed disappointment that our recent listing of “Some Warfarin Drug Interactions” 1 did not include acetaminophen. Perhaps it should have. Acetaminophen can increase the anticoagulant effect of warfarin, particularly with continued use, but it does so inconsistently. The mechanism of this interaction has not been established, but may be related to an acetaminophen metabolite inhibiting vitamin K-epoxide reductase, the target for warfarin’s anticoagulant effect. 2 Patient susceptibility varies, possibly on a genetic basis; occasional use of acetaminophen generally has little or no effect on the international normalized ratio (INR) in patients on chronic warfarin therapy, but in some, even a few grams of the drug may cause a dramatic increase in INR. One study in healthy subjects found no effect of acetaminophen 4 g per day for 2 weeks, while another study in patients with the same acetaminophen dose for the same period of time found a moderate increase in INR. 3,4 It might be prudent to monitor INR in patients on chronic warfarin therapy more closely than usual when they take more than 2 g per day of acetaminophen for more than a few days. 1. Pharmacogenetic-based dosing of warfarin. Med Lett Drugs Ther 2008; 50:39. 2. HH Thijssen et al. Paracetamol (acetaminophen) warfarin interaction: NAPQI, the toxic metabolite of paracetamol, is an inhibitor of enzymes in the vitamin K cycle. Thromb Haemost 2004; 92:797. 3. D Kwan et al. The effects of acetaminophen on pharmacokinetics and pharmacodynamics of warfarin. J Clin Pharmacol 1999; 39:68. 4. I Mahe et al. Paracetamol: A haemorrhagic risk factor in patients on warfarin. Br J Clin Pharmacol 2005; 59:371. Download U.S. English
Issue 1286 · May 19, 2008
Pharmacogenetic-Based Dosing of Warfarin

Warfarin sodium ( Coumadin , and others) and other coumarin anticoagulants prevent thrombosis, but patient response is highly variable and overanticoagulation can lead to hemorrhage. Genotyping patients for…

Med Lett Drugs Ther. 2008 May 19; 50(1286):39-40
Warfarin sodium ( Coumadin , and others) and other coumarin anticoagulants prevent thrombosis, but patient response is highly variable and overanticoagulation can lead to hemorrhage. Genotyping patients for single nucleotide polymorphisms (SNPs) that affect coumarin metabolism and sensitivity may help clinicians estimate the therapeutic warfarin dose. The FDA has added a note to warfarin labeling recommending lowrange doses for patients with such genetic variations. Commercial tests for these variants are now available and cost about $500 per test.
Issue 58 · June 1, 2007
Drugs for Cardiac Arrhythmias

The drugs of choice for treatment of common cardiac arrhythmias are listed in Tables 1 and 2. Some drugs are recommended for indications that have not been approved by the FDA.

Treat Guidel Med Lett. 2007 Jun; 5(58):51-8
The drugs of choice for treatment of common cardiac arrhythmias are listed in Tables 1 and 2. Some drugs are recommended for indications that have not been approved by the FDA.
Issue 1226 · January 16, 2006
Drugs in the Elderly

The physiologic changes that occur with aging can affect the pharmacokinetics and pharmacodynamics of many prescription and over-the-counter drugs, increasing the likelihood of adverse effects.

Med Lett Drugs Ther. 2006 Jan 16; 48(1226):6-7
The physiologic changes that occur with aging can affect the pharmacokinetics and pharmacodynamics of many prescription and over-the-counter drugs, increasing the likelihood of adverse effects.
Issue 1219 · October 10, 2005
Tipranavir (Aptivus) for HIV

Tipranavir ( Aptivus - Boehringer Ingelheim), a new protease inhibitor, has received accelerated approval from the FDA. It must be given with ritonavir ( Norvir ). The combination is indicated for use with…

Med Lett Drugs Ther. 2005 Oct 10; 47(1219):83-4
Tipranavir ( Aptivus - Boehringer Ingelheim), a new protease inhibitor, has received accelerated approval from the FDA. It must be given with ritonavir ( Norvir ). The combination is indicated for use with other antiretrovirals to treat HIV infection in highly treatment-experienced adults who have ongoing viral replication or in those with HIV strains known to be resistant to multiple protease inhibitors.
Issue 1212 · July 4, 2005
CYP3A and Drug Interactions

Serious adverse interactions between drugs continue to be reported. Many of these are due to inhibition or induction of cytochrome P450 (CYP) enzymes, particularly CYP3A4. CYP3A is thought to be involved in…

Med Lett Drugs Ther. 2005 Jul 4; 47(1212):54-5
Serious adverse interactions between drugs continue to be reported. Many of these are due to inhibition or induction of cytochrome P450 (CYP) enzymes, particularly CYP3A4. CYP3A is thought to be involved in the metabolism of more than 50 percent of currently prescribed drugs.2 CYP3A4, which is more abundantly expressed than CYP3A5, accounts for most CYP3A activity in vivo .
Issue 1196 · November 22, 2004
Safety of Aggressive Statin Therapy

New guidelines from The National Cholesterol Education Program recommend, as a therapeutic option, lowering treatment goals for LDL cholesterol (LDL-C) from <100 mg/dL to <70 mg/dL for patients at very high…

Med Lett Drugs Ther. 2004 Nov 22; 46(1196):93-5
New guidelines from The National Cholesterol Education Program recommend, as a therapeutic option, lowering treatment goals for LDL cholesterol (LDL-C) from <100 mg/dL to <70 mg/dL for patients at very high risk for coronary heart disease and from 130 mg/dL to <100 mg/dL for those at moderately high risk. A likely consequence of these recommendations is increased use of statins and use of higher doses with a concomitant increase in adverse effects.
Issue 27 · November 1, 2004
Drugs for Cardiac Arrhythmias

The drugs of choice for treatment of common cardiac arrhythmias are listed in the table that begins on the next page; some drugs are recommended for indications for which they have not been approved by the US…

Treat Guidel Med Lett. 2004 Nov; 2(27):75-82
The drugs of choice for treatment of common cardiac arrhythmias are listed in the table that begins on the next page; some drugs are recommended for indications for which they have not been approved by the US FDA. The dosages and adverse effects of each drug are listed in the table that begins on page 80. Antiarrhythmic drugs may themselves cause arrhythmias, which can be fatal. Some of these drugs may increase rather than decrease mortality, especially in patients with structural heart disease.
Issue 1173 · January 5, 2004
Drug Interactions with Grapefruit Juice

The ability of grapefruit juice to increase serum concentrations of drugs was first discovered during a study of the effect of ethanol on felodipine (Plendil) pharmacokinetics. Double-strength grapefruit juice…

Med Lett Drugs Ther. 2004 Jan 5; 46(1173):2-4
The ability of grapefruit juice to increase serum concentrations of drugs was first discovered during a study of the effect of ethanol on felodipine (Plendil) pharmacokinetics. Double-strength grapefruit juice used to disguise the taste of ethanol resulted in higher than expected serum concentrations of felodipine (DG Bailey et al, Clin Invest Med 1989; 12:357).
Issue 1166 · September 29, 2003
Vardenafil (Levitra) for Erectile Dysfunction

Vardenafil (Levitra -Bayer) is the second oral drug approved by the FDA for treatment of erectile dysfunction. Sildenafil (Viagra - Medical Letter 1998; 40:51), the first oral drug, has been available for 5…

Med Lett Drugs Ther. 2003 Sep 29; 45(1166):77-8
Vardenafil (Levitra -Bayer) is the second oral drug approved by the FDA for treatment of erectile dysfunction. Sildenafil (Viagra - Medical Letter 1998; 40:51), the first oral drug, has been available for 5 years. Pharmacokinetics, effectiveness, adverse effects, dosage and cost of the new drug are reviewed. Whether it offers any benefits over sildenafil is discussed.
Issue 1158 · June 8, 2003
Drug Interactions

Changes caused by one drug in the absorption, distribution, metabolism or excretion of another may lead to a pharmacokinetic adverse drug interaction (DN Juurlink et al, JAMA 2003; 289:1652). Additive drug…

Med Lett Drugs Ther. 2003 Jun 8; 45(1158):46-8
Changes caused by one drug in the absorption, distribution, metabolism or excretion of another may lead to a pharmacokinetic adverse drug interaction (DN Juurlink et al, JAMA 2003; 289:1652). Additive drug interactions, such as vasodilation caused by both sildenafil (Viagra) and nitrates, can also have adverse effects.
Issue 4 · December 1, 2002
Cardiovascular Drugs in the ICU

Ever-increasing specialization has made it difficult for many physicians to keep up with therapeutic standards in intensive-care units (ICUs). This issue of Treatment Guidelines offers current recommendations…

Treat Guidel Med Lett. 2002 Dec; 0(4):19-24
Ever-increasing specialization has made it difficult for many physicians to keep up with therapeutic standards in intensive-care units (ICUs). This issue of Treatment Guidelines offers current recommendations for use of cardiovascular drugs in the ICU for treatment of hypertensive emergencies; shock, cardiac arrest or decompensated heart failure; and ventricular arrhythmias.
Issue 1144 · November 25, 2002
Indications for an Implantable Cardioverter Defibrillator

There is no longer any doubt that an implantable cardioverter defibrillator (ICD) can reliably terminate most life-threatening ventricular tachyarrhythmias. The remaining question is who should get one.…

Med Lett Drugs Ther. 2002 Nov 25; 44(1144):99-100
There is no longer any doubt that an implantable cardioverter defibrillator (ICD) can reliably terminate most life-threatening ventricular tachyarrhythmias. The remaining question is who should get one. Guidelines prepared by an American College of Cardiology/American Heart Association task force have recently been published (G Gregoratos et al, Circulation 2002; 106:2145).
Issue 1078 · May 15, 2000
Dofetilide for Atrial Fibrillation

Dofetilide (Tikosyn - Pfizer) , a new methanesulfonamide antiarrhythmic drug, has recently been marketed for oral treatment of atrial fibrillation and flutter.

Med Lett Drugs Ther. 2000 May 15; 42(1078):41-2
Dofetilide (Tikosyn - Pfizer) , a new methanesulfonamide antiarrhythmic drug, has recently been marketed for oral treatment of atrial fibrillation and flutter.
Issue 1057 · July 16, 1999
Amprenavir: A New HIV Protease Inhibitor

Amprenavir is the fifth protease inhibitor to become available for treatment of HIV infection. It was approved by the FDA for use with other drugs in the treatment of HIV-infected adults and children at least…

Med Lett Drugs Ther. 1999 Jul 16; 41(1057):63-6
Amprenavir is the fifth protease inhibitor to become available for treatment of HIV infection. It was approved by the FDA for use with other drugs in the treatment of HIV-infected adults and children at least four years old.
Issue 1056 · July 2, 1999
Drug Interactions

Reports of adverse interactions between drugs continue to accumulate. Recently, the FDA has expanded the recommendations on drug interactions found in the package inserts of new drugs.

Med Lett Drugs Ther. 1999 Jul 2; 41(1056):59-62
Reports of adverse interactions between drugs continue to accumulate. Recently, the FDA has expanded the recommendations on drug interactions found in the package inserts of new drugs.
Issue 985 · October 11, 1996
Drugs for Chronic Heart Failure

Cardiologist now emphasize the importance of neurohormonal as well as hemodynamic factors in the pathophysiology of chronic heart failure (JN Cohn, N Engl J Med, 335:490, August 15, 1996). Drugs that act on…

Med Lett Drugs Ther. 1996 Oct 11; 38(985):92-4
Cardiologist now emphasize the importance of neurohormonal as well as hemodynamic factors in the pathophysiology of chronic heart failure (JN Cohn, N Engl J Med, 335:490, August 15, 1996). Drugs that act on different mechanisms are commonly used together.
Issue 963 · December 8, 1995
Intravenous, Amiodarone

An intravenous formulation of amiodarone ( Cordarone IV -Wyeth-Ayerst) has been approved by the US Food and Drug Administration (FDA) for treatment and prophylaxis of recurrent ventricular fibrillation (VF) or…

Med Lett Drugs Ther. 1995 Dec 8; 37(963):114-5
An intravenous formulation of amiodarone ( Cordarone IV -Wyeth-Ayerst) has been approved by the US Food and Drug Administration (FDA) for treatment and prophylaxis of recurrent ventricular fibrillation (VF) or hemodynamically unstable ventricular tachycardia (VT) in patients refractory to other therapy.
Issue 893 · April 2, 1993
Sotalol for Cardiac Arrhythmias

Sotalol (hydrochloride ( Betapace -Berlex; Sotacor -Bristol Laboratories of Canada), an antiarrhythmic drug that prolongs repolarization (Class III) and also has beta-adrenergic-blocking activity (Class II),…

Med Lett Drugs Ther. 1993 Apr 2; 35(893):27-8
Sotalol (hydrochloride ( Betapace -Berlex; Sotacor -Bristol Laboratories of Canada), an antiarrhythmic drug that prolongs repolarization (Class III) and also has beta-adrenergic-blocking activity (Class II), was recently approved by the US Food and Drug Administration (FDA) for oral treatment of life-threatening ventricular arrhythmias.
Issue 875 · July 24, 1992
Flecainide for Supraventricular Tachyarrhythmias

Flecainide ( Tambocor -3M Pharmaceuticals), first introduced in 1985 for treatment of ventricular arrhythmias, was recently approved by the US Food and Drug Administration for oral use to prevent…

Med Lett Drugs Ther. 1992 Jul 24; 34(875):71-2
Flecainide ( Tambocor -3M Pharmaceuticals), first introduced in 1985 for treatment of ventricular arrhythmias, was recently approved by the US Food and Drug Administration for oral use to prevent supraventricular arrhythmias. The indications for using flecainide to treat ventricular arrhythmias were limited after a controlled trial found that post-myocardial infarction patients with asymptomatic ventricular arrhythmias who took the drug had twice as high a mortality rate as patients who took placebo (DS Echt et al, N Engl Med, 324:781, 1991).
Issue 866 · March 20, 1992
Drug Treatment of Cardiac Arrest

Cardiac arrest may be due to tachyarrhythmias, bradyarrhythmias, or asystole. Without treatment, permanent damage to the cerebral cortex usually begins within five minutes and is complete in ten. After…

Med Lett Drugs Ther. 1992 Mar 20; 34(866):30
Cardiac arrest may be due to tachyarrhythmias, bradyarrhythmias, or asystole. Without treatment, permanent damage to the cerebral cortex usually begins within five minutes and is complete in ten. After cardiopulmonary resuscitation (CPR) has been started and electrical defibrillation, when indicated, has been applied, drugs may help promote recovery.
Issue 827 · September 21, 1990
Drugs That Cause Pulmonary Toxicity

Some commonly used systemic drugs that may cause pulmonary toxicity are listed in the table below. These adverse effects may sometimes be difficult to distinguish from the underlying disease (JAD Cooper, Jr et…

Med Lett Drugs Ther. 1990 Sep 21; 32(827):88-90
Some commonly used systemic drugs that may cause pulmonary toxicity are listed in the table below. These adverse effects may sometimes be difficult to distinguish from the underlying disease (JAD Cooper, Jr et al, Am Rev Respir Dis, 133:321, 488, 1986). Pulmonary effects that are part of a generalized reaction or are indirect effects of drugs - on respiratory muscles, for example, or on the immune system - are not included here.